Abstracts Archive - Page 1785 of 2607 - ACR Meeting Abstracts

Abstract Number: 2794 • 2016 ACR/ARHP Annual Meeting
Sustained Complete Remission in Lupus Nephritis
Rattapol Pakchotanon¹, Dafna D. Gladman², Jiandong Su² and Murray Urowitz³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The durability of renal remission might be a predictor of good long-term renal outcome and survival in patients with lupus nephritis (LN). We aimed…
Abstract Number: 2795 • 2016 ACR/ARHP Annual Meeting
Effect of Complete or Partial Proteinuria Recovery Compared to No Recovery at 2 Years after the Diagnosis of Lupus Nephritis on Long Term Outcomes
Jorge Medina-Rosas¹, Dafna D. Gladman², Jiandong Su³, Murray Urowitz² and Zahi Touma², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis (LN) and it is an independent prognostic factor of long term outcomes. Recovery from…
Abstract Number: 2796 • 2016 ACR/ARHP Annual Meeting
Low Versus High Dose Glucocorticosteroid Used in Lupus Nephritis: Is There a Difference
Haifa Al-Sheikh¹, Dafna D. Gladman¹, Jiandong Su¹ and Murray Urowitz², ¹Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The exact dose of glucocorticoids (GC) needed for the management of lupus nephritis in an individual patient is unknown. We aimed to compare the…
Abstract Number: 2797 • 2016 ACR/ARHP Annual Meeting
Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus
Daniel J Wallace¹, Rosalind Ramsey-Goldman², Anca D. Askanase³, Susan Manzi⁴, Joseph Ahearn⁵, Richard Furie⁶, Arthur Weinstein⁷, Chaim Putterman⁸, Elena Massarotti⁹, Christopher Collins¹⁰, Kenneth Kalunian¹¹, Cristina Arriens¹², Stuart L. Silverman¹³, Smitha Reddy¹⁴, Puja Chitkara¹⁵, Claudia Ibarra¹⁶, Derren Barken¹⁷, Roberta Alexander¹⁸, John Conklin¹⁹ and Thierry Dervieux²⁰, ¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²FSM, Northwestern University, Chicago, IL, ³Medicine, Rheumatology, Columbia University Medical Center, New York, NY, ⁴Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ⁵Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, ⁶North Shore University Hospital, Great Neck, NY, ⁷Rheumatology Section, Washington Hospital Center, Washington, DC, ⁸Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁹Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ¹⁰MedStar Washington Hospital Center, Washington, DC, ¹¹Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ¹²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Cedars, Beverly Hills, CA, ¹⁴Arthritis Care and Research Center, Inc., Poway, CA, ¹⁵Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, ¹⁶Clinical Laboratory, Exagen Diagnostics, Vista, CA, ¹⁷Exagen Diagnostics, Vista, CA, ¹⁸Research & Development, Exagen Diagnostics, Vista, CA, ¹⁹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²⁰Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: A panel of autoantibodies in combination with C4d-bound complement activation products (CB-CAPs, EC4d and BC4d) has been established as a sensitive and specific testing…
Abstract Number: 2798 • 2016 ACR/ARHP Annual Meeting
Multi-Center Validation of Platelet Bound C4d, a Biomarker for Systemic Lupus Erythematosus
Richard Furie¹, Anca D. Askanase², Kenneth Kalunian³, Elena Massarotti⁴, Rosalind Ramsey-Goldman⁵, Daniel J Wallace⁶, Stuart L. Silverman⁷, Smitha Reddy⁸, Puja Chitkara⁹, Chaim Putterman¹⁰, Christopher Collins¹¹, Jill P. Buyon¹², Cristina Arriens¹³, Tyler O'Malley¹⁴, Roberta Alexander¹⁵, Derren Barken¹⁶, John Conklin¹⁷, Susan Manzi¹⁸, Joseph Ahearn¹⁹, Arthur Weinstein²⁰ and Thierry Dervieux¹⁴, ¹North Shore University Hospital, Great Neck, NY, ²Medicine, Rheumatology, Columbia University Medical Center, New York, NY, ³Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁴Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ⁵FSM, Northwestern University, Chicago, IL, ⁶Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars, Beverly Hills, CA, ⁸Arthritis Care and Research Center, Inc., Poway, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, ¹⁰Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ¹¹MedStar Washington Hospital Center, Washington, DC, ¹²Medicine, New York University School of Medicine, New York, NY, ¹³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Research and Development, Exagen Diagnostics, Vista, CA, ¹⁵Research & Development, Exagen Diagnostics, Vista, CA, ¹⁶Exagen Diagnostics, Vista, CA, ¹⁷1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ¹⁸Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁹Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, ²⁰Rheumatology Section, Washington Hospital Center, Washington, DC
Background/Purpose: Previous studies have established the value of measuring complement activation products (C4d) bound to platelets (PC4d) for the diagnosis and monitoring of Systemic Lupus…
Abstract Number: 2799 • 2016 ACR/ARHP Annual Meeting
Outcomes in Patients with Early and Delayed Onset Lupus Nephritis
Roaa ALJohani¹, Dafna D. Gladman¹, Jiandong Su¹ and Murray Urowitz², ¹Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare disease characteristics in patients with early and delayed onset of lupus nephritis(LN) and their outcomes after 5 years of follow-up. Methods: Patients…
Abstract Number: 2800 • 2016 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products in Multi-Analyte Assay with Algorithm Aid the Diagnosis of Systemic Lupus Erythematosus
James Mossell¹, John A. Goldman², Derren Barken³ and Roberta Alexander⁴, ¹Tift Regional Medical Center, Tifton, GA, ²Medical Quarters #293, Emory St. Joseph’s Hospital, Atlanta, GA, ³Exagen Diagnostics, Vista, CA, ⁴Research & Development, Exagen Diagnostics, Vista, CA
Background/Purpose: Cell-bound complement activation products (CB-CAPs) are sensitive and specific biomarkers in the differential diagnosis of systemic lupus erythematosus (SLE) and other rheumatic diseases, as…
Abstract Number: 2801 • 2016 ACR/ARHP Annual Meeting
Predictors of Incident Episodes of Proteinuria Among Patients with Systemic Lupus Erythematosus
Laurence S Magder¹, Ali Duarte-Garcia², Erik Barr³ and Michelle Petri⁴, ¹Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ²Medicine, Tufts Medical Center, Boston, MA, ³Epidemiology, University of Maryland, Baltimore, MD, ⁴Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis remains one of the most devastating SLE complications, occurring in over 50% of the patients. It is important to identify clinical conditions…
Abstract Number: 2802 • 2016 ACR/ARHP Annual Meeting
Comparison of the Clinical, Serological, and Prognostic Differences Among Juvenile-, Adult-, and Late-Onset Lupus Nephritis in Korean Patients: A Case-Control Study
Jeong-Won Lee¹, Ji-Hyoun Kang², Dong-Jin Park², Yi-Rang Yim¹, Ji-Eun Kim¹, Kyung-Eun Lee², Lihui Wen¹, Tae-Jong Kim³, Yong-Wook Park² and Shin-Seok Lee³, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of
Background/Purpose: SLE patients present with different clinical and serological manifestations according to the age at disease onset. However, it is not known whether there is…
Abstract Number: 2803 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical and Serological Differences According to the Autoantibody Cluster in Women with Systemic Lupus Erythematosus: Results from the Korean Lupus Network (KORNET) Registry
Ji-Eun Kim¹, Dong-Jin Park², Ji-Hyoun Kang², Yi-Rang Yim¹, Jeong-Won Lee¹, Kyung-Eun Lee², Lihui Wen¹, Tae-Jong Kim³, Yong-Wook Park² and Shin-Seok Lee³, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of
Background/Purpose: Individual autoantibodies are associated with the clinical features in patients with systemic lupus erythematosus (SLE). However, few studies have investigated differences in disease presentation…
Abstract Number: 2804 • 2016 ACR/ARHP Annual Meeting
Predictors of Survival in Renal Transplantation for Lupus Nephritis – 40 Patients in 40 Years
Eleana Ntatsaki¹, Alba Velo Garcia², Borja del Carmelo Gracia Tello Sr.³, Alan D. Salama⁴ and David A. Isenberg⁵, ¹Centre for Rheumatology, University College London, London, United Kingdom, ²Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, ³Internal Medicina, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, ⁴Centre for Nephrology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), leading to end stage renal failure…
Abstract Number: 2805 • 2016 ACR/ARHP Annual Meeting
Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment
Chee Ken Cheah¹, Shirish Sangle (Joint First Author)¹, Alina Casian², Oier Barrutia¹, Munther Khamashta¹ and David D'Cruz¹, ¹Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ²Rheumatology, Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) complicates 60% of systemic lupus erythematosus (SLE) patients within 5 years of diagnosis. Glucocorticoids and disease modifying immunosuppressive drugs (IS) are…
Abstract Number: 2806 • 2016 ACR/ARHP Annual Meeting
A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study
John A. Reynolds^1,2, Mumtaz Khan³, Tracy A. Briggs⁴, Gillian Rice⁵, Yanick Crow⁵, Ben Parker⁶ and Ian N. Bruce^1,7, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁴Institute of Human Development, University of Manchester, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Institute of Human Development, University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁷Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Type I interferon has been implicated in the pathogenesis of systemic lupus erythematosus (SLE), but much less is known about its role in other…
Abstract Number: 2807 • 2016 ACR/ARHP Annual Meeting
Skin and Muscle Sodium Concentrations in Patients with Systemic Lupus Erythematosus: A Proof of Concept Study
Cecilia P. Chung¹, Michelle J. Ormseth¹, Annette M. Oeser¹, Ping Wang², John C. Gore², Jens Titze¹ and C. Michael Stein¹, ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Radiology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Results: SLE (n=7) Controls (n=8) p-value Age 41 (32-56) 34 (28-47) 0.42 Female n (%) 6 (86%) 7 (88%) 0.73 Systolic blood…
Abstract Number: 2808 • 2016 ACR/ARHP Annual Meeting
Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus
Shunsei Hirohata¹, Yuko Sakuma², Tamiko Yanagida³ and Taku Yoshio⁴, ¹Kitasato University School of Medicine, Sagamihara, Japan, ²Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ³Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁴Jichi Medical University, Tochigi, Japan
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].